Generic Medicine Info
Indications and Dosage
Prophylaxis of hypotension during anaesthesia
Adult: 10-15 mg shortly before or with spinal anaesthesia. Up to 20 mg may be required at high levels of anaesthesia. About 15 min should elapse before repeating a dose.

Hypotensive states
Adult: As hydrochloride: Moderate hypotension: 5-10 mg.

Hypotensive states
Adult: As hydrochloride: Emergency: 3-5 mg by slow inj. May be supplemented by IM inj for a more prolonged effect. About 15 min should elapse before repeating a dose.

Paroxysmal supraventricular tachycardia
Adult: As hydrochloride: 10 mg by slow inj over 3-5 min.
Severe hypertension.
Special Precautions
Hyperthyroidism, bradycardia, partial heart block, myocardial disease, poor left ventricular function, severe arteriosclerosis, pre-existing vascular disease. Pregnancy and lactation.
Adverse Reactions
Excessive BP elevations particularly with high dosage, ventricular ectopic beats, reflex bradycardia; nausea, vomiting; headache (often severe), anxiety; sweating, pilomotor response; feeling of cold and other skin sensations resulting from piloerection; uterine hypertonus, fetal bradycardia, urinary urgency.
Symptoms: Undesirable elevations in BP and/or bradycardia. Management: α-adrenergic blocking agent (e.g. phentolamine) may be used for severe hypertension. Bradycardia may be abolished by atropine.
Drug Interactions
Potentiation of pressor effects with MAOIs, TCAs, vasopressin, ergotamine, ergonovine or methylergonovine, sympathomimetic decongestants, certain appetite suppressants and amphetamine-like psychostimulants.
Lab Interference
May increase plasma cortisol and adrenocorticotropic hormone (ACTH) levels; use caution when interpreting plasma cortisol and ACTH levels.
Description: Methoxamine has mainly direct effects on α-adrenergic receptors. It causes prolonged peripheral vasoconstriction and consequently a rise in arterial BP.
Onset: IV: Within 0.5-2 min. IM: Within 15-20 min.
Duration: IV: 10-15 min. IM: 1.5 hr.
Store at controlled room temperature (15-30°C). Protect from light.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Methoxamine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in